CriticalAntidepressants. Other antidepressants of herbal origin×SNRI (serotonin-norepinephrine reuptake inhibitor)
Updated · Methodology
Mechanism
St John's wort extract inhibits the synaptosomal reuptake of serotonin, noradrenaline and dopamine (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Venlafaxine and its main metabolite also inhibit serotonin and noradrenaline reuptake (venlafaxine SmPC, AEMPS, section 5.1). The interaction table of the St John's wort SmPC lists increased serotonergic effects and a higher incidence of adverse reactions with venlafaxine (St John's wort SmPC, AEMPS, section 4.5), and the venlafaxine SmPC lists St John's wort among serotonergic agents that can lead to serotonin syndrome (venlafaxine SmPC, AEMPS, sections 4.4 and 4.5). Hyperforin in St John's wort induces the enzyme CYP3A4 (St John's wort SmPC, AEMPS, section 5.2). Venlafaxine is converted to its main active metabolite by CYP2D6, while CYP3A4 forms only a minor, less active metabolite (venlafaxine SmPC, AEMPS, section 5.2). The documents give no data on how St John's wort changes venlafaxine levels.
Symptoms
According to the Spanish venlafaxine summary of product characteristics (SmPC), serotonin syndrome is a potentially life-threatening condition. It presents with mental status changes (agitation, hallucinations, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (hyperreflexia, incoordination), nausea, vomiting and diarrhoea (venlafaxine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). In its most severe form the syndrome may resemble neuroleptic malignant syndrome, with hyperthermia, muscle rigidity, rapid fluctuations of vital signs and mental status changes (venlafaxine SmPC, AEMPS, section 4.4). The venlafaxine label of the US Food and Drug Administration (FDA) also lists delirium, dizziness, sweating, flushing, tremor, myoclonus and seizures (FDA venlafaxine label, section 5.2). According to the European Medicines Agency (EMA) herbal monograph, the syndrome occurs very rarely with serotonergic medicines (St John's wort herbal monograph, EMA, section 4.5).
Management
The Spanish St John's wort summary of product characteristics (SmPC) contraindicates the combination: St John's wort must not be used with antidepressants, and its interaction table names venlafaxine (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of this product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The venlafaxine SmPC is less strict: if combination with other serotonergic agents is clinically warranted, observe the patient carefully, particularly at the start of treatment and after dose increases (venlafaxine SmPC, AEMPS, section 4.4). If signs of serotonin syndrome appear, stop venlafaxine and other serotonergic medicines immediately and start symptomatic treatment (venlafaxine label, US Food and Drug Administration, FDA, section 5.2). No document says how long to wait between stopping St John's wort and starting venlafaxine. Increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, European Medicines Agency, EMA, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Effexor XR (venlafaxine) prescribing information (2023)– FDA label, Viatris Specialty LLC, DailyMed setid c848a5d8-ba94-4c84-80e3-0bf35fb8e32e, revised 08/2023, sections 5.4, 7 and 17
- AEMPS: Ficha técnica: Vandral Retard 75 mg (venlafaxina, nº registro 62401), sección 4.5 (2024)– AEMPS, CIMA, nº registro 62401, revisión 05/2024, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5